Analysis of outcomes achieved with squamous cell carcinomas of the anus in a single university hospital over the last two decades: Clinical response rate, relapse and survival of 190 patients
- 10 September 2017
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 117 (2) , 269-274
Abstract
Background and Objectives: We reviewed our series of anal squamous cell carcinomas (ASCC) treated over the last two decades.Methods: ASCC patients undergoing treatment at the Leicester Royal Infirmary between 1998 and 2016 were selected. Age, gender, pathological tumor characteristics, treatment adopted, the overall survival (OS), cancer‐specific survival (CSS), and disease‐free survival (DFS) at 5‐year follow‐up were recorded and calculated.Results: A total of 190 ASCC were reviewed, of these 64.2% (n = 122) received primary radical chemoradiotherapy. Complete response rate was 92.6% (n = 113) and four patients with residual disease underwent a salvage APER. Twenty‐eight patients experienced recurrent disease (23.0%) either systemic (n = 8), local (n = 14), or both (n = 6); six had a salvage APER. Complete follow‐up data are available for 63.1% patients (77/122). Overall, the locoregional failure rate of primary chemoradiotherapy (residual + recurrent disease) was present in 29 patients (29/122; 23.8%). OS was 41.6% CSS was 69.2% and DFS 60.0% at 5 years follow‐up.Conclusions: In our series of ASCC primary chemoradiotherapy had achieved significant initial complete response rates, however, long term‐follow ups still present systemic and local recurrences. APR is able to treat 30% of the pelvic recurrences (6/20), the others are either associated with systemic disease or locally inoperable masses.Keywords
This publication has 18 references indexed in Scilit:
- Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and BehaviorCancer Epidemiology, Biomarkers & Prevention, 2015
- Anal cancer: Current standards in care and recent changes in practiceCA: A Cancer Journal for Clinicians, 2015
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trialThe Lancet Oncology, 2013
- Prognostic factors for recurrence and survival in anal cancerCancer, 2012
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- “Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Abdomino-Perineal Resection for Anal CancerAnnals of Surgery, 2009
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysisInternational Journal of Cancer, 2009
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA, 2008
- Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973–2000Cancer, 2004